Management of Tuberculosis in Pre-existing Liver Disease

Introduction

Why Pre-existing Liver Disease Increases Risk

Key principle: Abnormal baseline aminotransferases alone are an independent risk factor for DILI. — Murray & Nadel's Textbook of Respiratory Medicine, p.1220

Hepatotoxicity Profiles of Individual First-Line Drugs

General Principles of Management

1. Always attempt to use INH and RIF — their efficacy warrants use even with pre-existing liver disease; avoid only if there is absolutely no hepatic reserve.
2. Expert consultation is mandatory for severe or unstable liver disease.
3. Baseline testing before starting treatment (for all patients):
   • Serum ALT/AST, total bilirubin, alkaline phosphatase
   • Serum creatinine
   • Blood platelet count
   • For severe hepatic impairment: add prothrombin time / INR
4. Stratify by degree of liver disease to select the appropriate regimen.

Regimen Selection Based on Severity of Liver Disease

Tier 1: Mild-Moderate Liver Disease (ALT < 3× ULN, or stable chronic disease)

• Standard 6-month regimen (2HRZE / 4HR) can be used with intensified monitoring.
• Some clinicians omit PZA and extend to 9 months if there is concern.

Tier 2: ALT > 3× ULN — Treatment Without PZA

• Regimen: INH + RIF + EMB × 2 months (intensive phase), then INH + RIF × 4 more months (total = 9 months)
• EMB continued until drug susceptibility testing confirms INH and RIF sensitivity.
• Rationale: PZA is the drug most commonly implicated in serious DILI; removing it substantially reduces hepatotoxic burden while preserving the two most efficacious bactericidal agents.

Tier 3: Advanced Liver Disease (e.g., cirrhosis, ALT markedly elevated) — Treatment Without INH and PZA

• Regimen: RIF + EMB + Fluoroquinolone (levofloxacin or moxifloxacin) ± cycloserine × 12–18 months
• Duration depends on extent of disease and treatment response.
• RIF is preserved as the sterilizing backbone.
• Injectable agents (amikacin/streptomycin) may be added but: some experts avoid aminoglycosides in severe, unstable liver disease due to concerns about renal insufficiency, thrombocytopenia, and coagulopathy.

Tier 4: Severe, Unstable Liver Disease — Regimen With Little or No Hepatotoxicity

• Regimen: EMB + Fluoroquinolone + Cycloserine + Second-line injectable × 18–24 months
• This is essentially an MDR-TB type regimen in a drug-sensitive patient.
• INH, RIF, and PZA are all avoided.
• Risk: Longer duration, more side effects, potential for acquired resistance if adherence lapses.

Murray & Nadel's Textbook of Respiratory Medicine, p.1220–1221; ATS Official Statement on Hepatotoxicity of Antituberculous Therapy

Monitoring During Treatment

When to Stop Anti-TB Drugs (DILI Criteria)

• Symptoms of hepatitis plus ALT >3× ULN, OR
• Asymptomatic ALT >5× ULN, OR
• Any jaundice (bilirubin rise) with or without symptoms.

Drug-Induced Liver Injury During Treatment — Rechallenge Strategy

1. Hold all hepatotoxic drugs when DILI is confirmed; substitute with non-hepatotoxic regimen (EMB + fluoroquinolone ± cycloserine) as a "holding" regimen to prevent disease progression.
2. Wait for LFTs to normalize (ALT <2× ULN, bilirubin normal).
3. Sequential reintroduction starting with the least hepatotoxic drug:
   • RIF first (often tolerated; most critical) → monitor LFTs for 1 week
   • Then INH → monitor LFTs for 1 week
   • PZA is usually not reintroduced if it was the likely causative agent.
4. If LFTs rise again with any drug → that drug is permanently withdrawn, and a non-hepatotoxic regimen is completed for the required duration.

Special Scenarios

TB with Viral Hepatitis (Hepatitis B or C Co-infection)

• Higher risk of DILI; use regimen based on baseline ALT as above.
• Active HBV/HCV should be treated concurrently or sequentially depending on severity.
• Rifampicin and rifapentine are contraindicated in patients on protease inhibitors (PIs) or most NNRTIs (nevirapine) due to drug-drug interactions.
• During TB treatment, transaminase elevation may represent coincidentally developing acute hepatitis A, B, or C — serological testing is warranted.

Liver Transplant Recipients

• Higher risk of DILI post-transplant.
• Rifampicin strongly induces CYP3A4 → drastically lowers calcineurin inhibitor (tacrolimus, cyclosporine) levels → risk of rejection.
• Preferred regimen: INH + EMB + ofloxacin/fluoroquinolone for 18 months (without rifampicin).
• If rifampicin must be used (non-CNI-based immunosuppression), double the maintenance prednisolone dose.

Alcoholic Liver Disease

• Alcohol itself is hepatotoxic and compounds DILI risk from INH.
• Counsel on alcohol cessation; use Tier 2 or Tier 3 regimen depending on extent of disease.
• Pyridoxine (50 mg/day) is especially important given combined nutritional deficiency and INH-related B6 depletion.

Summary Table: Regimen Selection by Hepatic Severity

Key Points for Exam

1. PZA is the most hepatotoxic first-line drug and is eliminated first.
2. INH and RIF should be preserved as long as hepatic reserve allows.
3. Baseline ALT >3× ULN (not from TB) is the threshold to modify regimen.
4. Monitoring every 1–4 weeks for first 2–3 months is mandatory in pre-existing liver disease.
5. Rechallenge after DILI: RIF first → then INH; PZA usually not reintroduced.
6. Rifampicin + calcineurin inhibitors is a dangerous interaction (liver transplant).
7. Fluoroquinolones and cycloserine are the backbone of hepatotoxicity-sparing regimens.
8. Duration is inversely related to the number of effective hepatotoxic drugs retained — the fewer used, the longer the treatment.
9. Hepatic TB elevating LFTs should not be misidentified as DILI — LFTs improve with treatment.
10. Expert consultation is mandatory for severe or unstable liver disease.